A Low Fasting Glucose/Estimated Average Glucose Ratio was Associated with Superior Response to Insulin Degludec/Aspart Compared to Basal Insulin in Patients with Type 2 Diabetes.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of diabetes investigation"
DOI: 10.1111/jdi.13634
Abstract: INTRODUCTION Benefits of once-daily insulin degludec/aspart (IDegAsp) compared to basal insulin in type 2 diabetes has not been established. MATERIALS AND METHODS This is a retrospective observational study. From a basal insulin cohort from 3… read more here.
Keywords: insulin; degludec aspart; control; compared basal ... See more keywords